Johnson & Johnson (JNJ)

Over the past six months, Johnson & Johnson's stock has shown positive performance, with a share price of $188.64 as of October 3, 2025, marking a 17.69% increase from October 4, 2024. Key events impacting the stock include exceeding Wall Street's forecasts in Q1 2024 due to increased medical device sales and a dividend increase, the acquisition of Shockwave Medical, FDA approval for TREMFYA, an analyst upgrade by Wells Fargo, and the upcoming U.S. patent expiration of Stelara.

The demand for Johnson & Johnson's products and services exhibits varying degrees of seasonality. Consumer health products experience increased demand during the cough and cold season, while medical device demand can be influenced by elective surgeries. Pharmaceutical product demand is generally high due to the ongoing need for treatments across various therapeutic areas. Johnson & Johnson actively works to manage demand fluctuations by transforming its demand planning function.

Johnson & Johnson (JNJ) is a multinational corporation specializing in pharmaceuticals, biotechnology, and medical technologies. The company operates primarily within the healthcare sector, segmented into Innovative Medicine and MedTech, and is involved in the research, development, manufacture, and sale of healthcare products. The Innovative Medicine segment focuses on therapeutic areas such as immunology, infectious diseases, neuroscience, oncology, and cardiovascular diseases, featuring brands like Darzalex, Erleada, Tremfya, and Spravato. The MedTech segment offers products for cardiovascular, orthopedic, neurovascular care, general surgery, and vision care, including brands like Ethicon, DePuy Synthes, and Acuvue. The Consumer Health segment, which included brands like Band-Aid, Aveeno, and Tylenol, was spun off into a separate company called Kenvue in 2023.

Johnson & Johnson has a substantial global presence, operating in over 60 countries with approximately 138,000 employees worldwide. The company's manufacturing units are located across the United States, Europe, Asia-Pacific, Africa, the Western Hemisphere, and Latin America. Its headquarters are in New Brunswick, New Jersey, U.S. Johnson & Johnson also maintains a global network of Innovation Centers and JLABS locations.

Johnson & Johnson has consistently maintained a strong brand reputation within the healthcare industry. In January 2024, the company was named a Fortune World's Most Admired Company for the 22nd consecutive year. Recent reports primarily focus on positive business developments, pipeline advancements, and continued recognition for its industry leadership.

Institutional investors hold approximately 73% of Johnson & Johnson's outstanding shares, with the largest shareholders including The Vanguard Group, Inc., BlackRock, Inc., and State Street Corporation. Individual investors hold approximately 27% of the shares, while insiders own less than 1% of the company.